Jonathan Katz, MD
Neurology · San Francisco, CANPI 1457372823
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $190,437 of the $293,738 with a category attached, or 64.8%. 27 manufacturers reported payments, led by Grifols USA, LLC at 42.0% of the total. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $982.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$123K
- Tanabe Pharma America, Inc.$35K
- Janssen Research & Development, LLC$29K
- AstraZeneca$25K
- Biogen$14K
- Argenx US, Inc.$11K
- plus $55K from 21 others
Across 162 payments — averaging $8627.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$479K
- UCB SA$256K
- Genentech, Inc.$160K
- Sanofi$137K
- PTC Therapeutics, Inc.$109K
- AstraZeneca$56K
- plus $201K from 8 others
What the payments were for
- Consulting fees$190,43765%
- Speaking & faculty fees$57,90320%
- Travel & lodging$36,43812%
- Food & beverage$8,8983%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 65 | $123,254 |
| Tanabe Pharma America, Inc. | 68 | $35,175 |
| Janssen Research & Development, LLC | 3 | $29,400 |
| AstraZeneca(2 entities) | 46 | $25,474 |
| Biogen | 18 | $14,394 |
| Argenx US, Inc. | 21 | $10,995 |
| Novavax Inc | 1 | $10,500 |
| Sanofi | 3 | $10,410 |
| UCB, Inc. | 11 | $7,740 |
| Johnson & Johnson | 3 | $5,358 |
| CSL Behring | 7 | $4,734 |
| Shire North American Group Inc | 4 | $3,689 |
| Amgen | 3 | $3,513 |
| Grifols Shared Services North America, Inc. | 3 | $2,141 |
| Pfizer | 3 | $1,611 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,600 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 9 | $1,413 |
| PTC Therapeutics, Inc. | 3 | $956 |
| EDW Pharma, Inc. | 1 | $483 |
| Amylyx Pharmaceuticals, Inc. | 5 | $300 |
| Alnylam Pharmaceuticals Inc. | 10 | $235 |
| Akcea Therapeutics, Inc. | 2 | $149 |
| Avanir Pharmaceuticals, Inc. | 3 | $68 |
| SK Life Science, Inc. | 2 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Baxter Healthcare | 1 | $30 |
| Upsher-smith Laboratories LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Gamunex-C$115,746
- Radicava$25,951
- SOLIRIS$20,191
- NOVAVAX COVID-19 VACCINE, ADJUVANTED$10,500
- Xembify$9,042
- VYVGART$7,789
- SPINRAZA$7,115
- Radicava ORS$5,949
- Hizentra$4,587
- GAMMAGARD LIQUID$3,578
- UPLIZNA$3,438
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$1,480
- Tiglutik$483
- RELYVRIO$140
- TEGSEDI$119
How this compares
$293,738 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 150 | $2,101,781 |
| ActharCorticotropin | 12 | $903,502 |
| EvrysdiRisdiplam | 25 | $788,937 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 57 | $615,297 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 31 | $554,776 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 68 | $471,257 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 24 | $298,638 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 16 | $128,105 |
| Riluzole | 127 | $23,966 |
| Azathioprine | 43 | $12,763 |
| Mycophenolate Mofetil | 43 | $3,507 |
| Gabapentin | 121 | $1,996 |
| Atropine Sulfate | 14 | $1,499 |
| Levetiracetam | 21 | $1,131 |
| Pyridostigmine Bromide | 17 | $1,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $123,254 | $615,29757 claims |
| CSL BehringPrivigen | $4,734 | $554,77631 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $300 | $298,63824 claims |
| PfizerOctagam | $1,611 | $128,10516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.